Immune reconstitution efficacy after combination antiretroviral therapy in male HIV-1 infected patients with homosexual and heterosexual transmission
Year: 2023
Type: dataset
Abstract: We aimed to explore the impact of sexual transmission modes on immune reconstitution after combined antiretroviral therapy (cART). We have retrospectively analyzed longitudinal samples from 1557 treated male patients with virological suppression (HIV-1 RNA<50 copies/ml) for at least 2 years. Both heterosexuals (HET) and men who have sex with men (MSM) patients showed an increasing annual trend in CD4+ T cell counts after receiving cART (HET, β: 23.51 (cell/µl)/year, 95% CI: 16.70 to 30.31; MSM, β: 40.21 (cell/µl)/year, 95% CI: 35.82 to 44.61). However, the CD4+ T cell recovery rate was much lower in HET patients than MSM patients, determined by both the generalized additive mixed model (P < 0.001) and generalized estimating equations (P = 0.026). Besides HIV-1 subtypes, baseline CD4+ T cell counts and age at cART initiation, HET was an independent risk factor for immunological non-responders (adjusted OR: 1.73; 95% CI: 1.28 to 2.33). HET was also associated with lower probability of achieving conventional immune recovery (adjusted HR: 1.37; 95%CI: 1.22 to 1.67) and optimal immune recovery (adjusted HR: 1.48, 95%CI: 1.04-2.11). Male HET patients might have poorer immune reconstitution ability even after effective cART. Early initiation of cART after diagnosis and clinical monitoring for male HET patients should be highly emphasized.
Source: Figshare
Institutions: Southeast University, Tongji University, University of Science and Technology of China, Central South University, Shenzhen University, Shanghai Jiao Tong University, Wuhan University of Technology, Chinese Academy of Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, China-Japan Friendship Hospital, First Affiliated Hospital of Wenzhou Medical University, Wuhan University, First Affiliated Hospital of Xiamen University, Fred Hutch Cancer Center, Institute of Hydrobiology, Jiaxing University, Changchun Institute of Applied Chemistry, Suzhou Institute of Systems Medicine, First Hospital of Jilin University, Shanghai East Hospital, Peking University First Hospital, Second Affiliated Hospital of Nanjing Medical University, First Hospital of China Medical University, Institute of Hydrobiology, Biology Centre, Academy of Sciences of the Czech Republic, Huaiyin Normal University, First Affiliated Hospital of Bengbu Medical College, Jiangsu Province Hospital, First Affiliated Hospital of Soochow University, Second Xiangya Hospital of Central South University, Second Affiliated Hospital of Zhejiang University, University of Chinese Academy of Sciences, Huazhong University of Science and Technology, Southern Medical University, East China Normal University, Zhejiang University, Nanjing Medical University, University of Electronic Science and Technology of China, Capital Medical University, Anhui Medical University, Guangzhou University, Jinshan Hospital of Fudan University, International Peace Maternity & Child Health Hospital, Zhongnan Hospital of Wuhan University, First Affiliated Hospital of GuangXi Medical University, Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Chengdu Fifth People's Hospital, The Ohio State University, Nanjing University, Jiangsu Provincial Center for Disease Control and Prevention, Renmin Hospital of Wuhan University, Nanjing University of Chinese Medicine, Jinan University, South China Normal University, Gansu Provincial Maternal and Child Health Hospital, First Affiliated Hospital of Chengdu Medical College, Jiangsu Cancer Hospital, Fujian Agriculture and Forestry University, Shanghai Sixth People's Hospital
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4394243025